Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

1 year ago

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor TypesProlonged stable disease lasting >11 months demonstrated in Breast…

Health Systems Brace for Significant 2025 Cost Surge, Shift to GPOs and Outsourcing for Supply Chain Solutions, Black Book Survey Finds

1 year ago

Hospitals are not just outsourcing procurement but also forming deeper strategic partnerships with GPOs. These partnerships go beyond price negotiation…

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

1 year ago

Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September 16,…

Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date

1 year ago

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed…

Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7 – in Europe

1 year ago

Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed…

Masimo Shares Final Thoughts Ahead of September 19 Annual Meeting Where Everything is at Stake

1 year ago

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products,…

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

1 year ago

Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with…

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

1 year ago

Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints…

KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions

1 year ago

RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is cementing its…

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

1 year ago

Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved medicine and 30 medicines…